Nama's AI scorecard currently rates Oscar Health Buy (7.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is OSCR's P/E ratio?

Oscar Health trades at a trailing price-to-earnings ratio of 12.7.

When does OSCR report earnings?

Oscar Health's next scheduled report is on Feb 10, 2027. Analysts expect EPS of -$1.08.

What is the OSCR price target?

The median analyst price target from 10 analysts is $34.00, with a range of $27.00 – $49.00.

Is OSCR Shariah compliant?

Nama's AAOIFI-style screen reads Oscar Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Oscar Health (OSCR)

Healthcare · Healthcare Plans · NYSE

Oscar Health (OSCR) is a Healthcare company in the Healthcare Plans industry. It has a market capitalization of $9.46B, a trailing price-to-earnings ratio of 12.7 and a free-cash-flow yield of 13.2%. Over the most recent reported fiscal year, revenue grew 27.5% and free cash flow per share grew 12.9%. Nama's AI scorecard rates it Buy, 7.7 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 7.7/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Leading · +98.7% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-20.4%

How far the last close sits under the highest price of the past five years.

Market cap	$9.46B
Trailing P/E	12.7
Price / book	4.6
Price / sales	0.6
FCF yield	13.2%
Dividend yield	—
Gross margin	20.2%
Operating margin	8.0%
Net margin	3.6%
Revenue growth (YoY)	+27.5%
Revenue growth (3-yr annual)	+41.5%
EPS growth (YoY)	—
FCF/share growth (YoY)	+12.9%
Beta	2.5
Exchange	NYSE
Sector	Healthcare
Industry	Healthcare Plans

OSCR earnings

Next report: Feb 10, 2027 (Q4 2026, EPS estimate -$1.08). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.49	-$0.17	+388.2%	—
Q2 2026	Aug 6, 2026	$1.10	$0.38	+189.5%	$4.88B
Q1 2026	May 6, 2026	$2.07	$1.10	+88.2%	$4.65B
Q4 2025	Feb 10, 2026	-$1.24	-$0.92	-34.8%	$2.81B

OSCR analyst price target

Median target $34.00 from 10 analysts, ranging $27.00 – $49.00.

Healthcare Plans peers

Ticker	Company	Market cap	P/E
UNH	UnitedHealth Group	$353.17B	19.3
CVS	CVS Health	$107.28B	10.1
ELV	Elevance Health	$91.96B	14.0
CI	Cigna Group	$77.58B	9.3
HUM	Humana	$52.08B	32.7
CNC	Centene	$34.53B	13.2
MOH	Molina Healthcare	$10.87B	104.5
PGNY	Progyny	$2.58B	17.0

Explore live OSCR data on Nama Insights →

OSCR FAQ

Is OSCR a buy?: Nama's AI scorecard currently rates Oscar Health Buy (7.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is OSCR's P/E ratio?: Oscar Health trades at a trailing price-to-earnings ratio of 12.7.
When does OSCR report earnings?: Oscar Health's next scheduled report is on Feb 10, 2027. Analysts expect EPS of -$1.08.
What is the OSCR price target?: The median analyst price target from 10 analysts is $34.00, with a range of $27.00 – $49.00.
Is OSCR Shariah compliant?: Nama's AAOIFI-style screen reads Oscar Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.